JRSIS HEALTH CARE Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that JRSIS HEALTH CARE Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $3.46M | Apr 26, 2024 |
| FY2023 | Dec 31, 2022 | $1.72M | Apr 26, 2024 |
| FY2021 | Dec 31, 2021 | $44.39M | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | $35.71M | Apr 15, 2022 |
| FY2018 | Dec 31, 2018 | $28.40M | Apr 1, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $24.15M | Apr 17, 2018 |
| FY2017 | Dec 31, 2016 | $18.12M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $11.87M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $5.98M | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | $4.35M | Mar 31, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $483.1K | Apr 26, 2024 |
| FY2023 | Dec 31, 2022 | $26.2K | Apr 26, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($80.9K) | Apr 26, 2024 |
| FY2023 | Dec 31, 2022 | ($575.8K) | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | $3.19M | Aug 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.83M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $888.1K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $1.99M | Jun 16, 2020 |
| FY2018 | Dec 31, 2017 | $4.65M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.47M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $1.79M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $611.5K | Mar 29, 2016 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($188.6K) | Apr 26, 2024 |
| FY2023 | Dec 31, 2022 | ($684.8K) | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | ($103.8K) | Aug 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.59M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $4.67M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $5.99M | Jun 16, 2020 |
| FY2018 | Dec 31, 2017 | $6.66M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $5.02M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $2.63M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $918.0K | Mar 29, 2016 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $189.3K | Apr 26, 2024 |
| FY2023 | Dec 31, 2022 | $283.0K | Apr 26, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $516.7K | Apr 26, 2024 |
| FY2023 | Dec 31, 2022 | ($1.76M) | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | $8.23M | Aug 31, 2023 |
| FY2021 | Dec 31, 2020 | $10.64M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $11.85M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $9.20M | Jun 16, 2020 |
| FY2018 | Dec 31, 2017 | $8.34M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.99M | Apr 17, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.5K | Apr 26, 2024 |
| FY2022 | Dec 31, 2022 | $44.6K | Aug 31, 2023 |
| FY2021 | Dec 31, 2021 | $2.31M | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | $8.27M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $4.71M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $3.28M | Jun 16, 2020 |
| FY2018 | Dec 31, 2017 | $2.59M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.48M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $5.15M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $3.59M | Mar 29, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.14M | Apr 26, 2024 |
| FY2023 | Dec 31, 2022 | $2.04M | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | $75.69M | Aug 31, 2023 |
| FY2021 | Dec 31, 2020 | $58.80M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $51.63M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $52.47M | Jun 16, 2020 |
| FY2018 | Dec 31, 2017 | $48.68M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $31.70M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $27.74M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $23.87M | Mar 29, 2016 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.31M | Apr 26, 2024 |
| FY2023 | Dec 31, 2022 | $2.11M | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | $42.59M | Aug 31, 2023 |
| FY2021 | Dec 31, 2020 | $29.96M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $28.64M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $30.43M | Jun 16, 2020 |
| FY2018 | Dec 31, 2017 | $28.45M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $20.02M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $20.32M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $18.88M | Mar 29, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($137.4K) | Apr 26, 2024 |
| FY2023 | Dec 31, 2022 | ($58.5K) | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | $22.07M | Aug 31, 2023 |
| FY2021 | Dec 31, 2020 | $19.04M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $14.82M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $14.14M | Jun 16, 2020 |
| FY2018 | Dec 31, 2017 | $12.89M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $6.63M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $3.69M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $1.99M | Mar 29, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($3.44M) | Apr 26, 2024 |
| FY2023 | Dec 31, 2022 | ($3.36M) | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | ($1.88M) | Aug 31, 2023 |
| FY2021 | Dec 31, 2020 | ($4.11M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($6.79M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $12.91M | Jun 16, 2020 |
| FY2018 | Dec 31, 2017 | $10.92M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $6.27M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $2.80M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $1.01M | Mar 29, 2016 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $58.6K | Aug 31, 2023 |
| FY2022 | Dec 31, 2021 | $29.8K | Aug 31, 2023 |
| FY2021 | Dec 31, 2020 | $844.8K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.97M | Apr 15, 2021 |
| FY2020 | Dec 31, 2018 | $256.5K | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | $884.3K | Jun 16, 2020 |
| FY2018 | Dec 31, 2016 | $890.7K | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $352.2K | Apr 17, 2018 |
| FY2016 | Dec 31, 2014 | $1.05M | Mar 29, 2017 |
| FY2015 | Dec 31, 2013 | $631.3K | Mar 29, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 26, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Aug 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Jun 16, 2020 |
| FY2014 | Dec 31, 2014 | 0 | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | 0 | Mar 31, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 26, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Aug 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Jun 16, 2020 |
| FY2014 | Dec 31, 2014 | 0 | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | 0 | Mar 31, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 82.59M | Apr 26, 2024 |
| FY2023 | Dec 31, 2022 | 76.76M | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | 18.63M | Aug 31, 2023 |
| FY2021 | Dec 31, 2020 | 18.25M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 17.98M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 14.98M | Jun 16, 2020 |
| FY2017 | Dec 31, 2017 | 14.84M | Apr 17, 2018 |
| FY2018 | Dec 31, 2016 | 14.84M | Apr 1, 2019 |
| FY2016 | Dec 31, 2015 | 13.92M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | 13.60M | Mar 29, 2016 |